Bühring KU, Sailer H, Faro HP, Leopold G, Pabst J, Garbe A (1986). “Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans”. J. Cardiovasc. Pharmacol.8 Suppl 11: S21–8. doi:10.1097/00005344-198511001-00004. PMID2439794.
Konishi, M.; Haraguchi, G.; Kimura, S.; Inagaki, H.; Kawabata, M.; Hachiya, H.; Hirao, K.; Isobe, M. (2010). “Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure”. Circulation journal : official journal of the Japanese Circulation Society74 (6): 1127–1134. doi:10.1253/circj.cj-09-0989. PMID20354334.
Leopold, G.; Pabst, J.; Ungethüm, W.; Bühring, K. U. (1986). “Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist”. Journal of clinical pharmacology26 (8): 616–621. doi:10.1002/j.1552-4604.1986.tb02959.x. PMID2878941.
“A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees”. Circulation90 (4): 1765–1773. (1994). doi:10.1161/01.cir.90.4.1765. PMID7923660.
Rosenberg, J.; Gustafsson, F. (2008). “Bisoprolol for congestive heart failure”. Expert Opinion on Pharmacotherapy9 (2): 293–300. doi:10.1517/14656566.9.2.293. PMID18201151.
Castagno, D.; Jhund, P. S.; McMurray, J. J. V.; Lewsey, J. D.; Erdmann, E.; Zannad, F.; Remme, W. J.; Lopez-Sendon, J. L. et al. (2010). “Improved survival with bisoprolol in patients with heart failure and renal impairment: An analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial”. European Journal of Heart Failure12 (6): 607–616. doi:10.1093/eurjhf/hfq038. PMID20354032.
Haeusler G, Schliep HJ, Schelling P (1986). “High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol”. J. Cardiovasc. Pharmacol.8 Suppl 11: S2–15. doi:10.1097/00005344-198511001-00002. PMID2439793.
Kaumann AJ, Lemoine H (October 1985). “Direct labelling of myocardial beta 1-adrenoceptors. Comparison of binding affinity of 3H-(−)-bisoprolol with its blocking potency”. Naunyn Schmiedebergs Arch. Pharmacol.331 (1): 27–39. doi:10.1007/bf00498849. PMID2866449.
Manalan AS, Besch HR, Watanabe AM (August 1981). “Characterization of [3H](+/-)carazolol binding to beta-adrenergic receptors. Application to study of beta-adrenergic receptor subtypes in canine ventricular myocardium and lung”. Circ. Res.49 (2): 326–36. doi:10.1161/01.res.49.2.326. PMID6113900.
Schliep HJ, Schulze E, Harting J, Haeusler G (April 1986). “Antagonistic effects of bisoprolol on several beta-adrenoceptor-mediated actions in anaesthetized cats”. Eur. J. Pharmacol.123 (2): 253–61. doi:10.1016/0014-2999(86)90666-7. PMID3011461.
Schliep HJ, Harting J (1984). “Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs”. J. Cardiovasc. Pharmacol.6 (6): 1156–60. doi:10.1097/00005344-198406060-00024. PMID6084774.
Wellstein A, Palm D, Belz GG (1986). “Affinity and selectivity of beta-adrenoceptor antagonists in vitro”. J. Cardiovasc. Pharmacol.8 Suppl 11: S36–40. doi:10.1097/00005344-198511001-00006. PMID2439796.
Bundkirchen A, Brixius K, Bölck B, Nguyen Q, Schwinger RH (January 2003). “Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies”. Eur. J. Pharmacol.460 (1): 19–26. doi:10.1016/S0014-2999(02)02875-3. PMID12535855.
Nuttall SL, Routledge HC, Kendall MJ (June 2003). “A comparison of the beta1-selectivity of three beta1-selective beta-blockers”. J Clin Pharm Ther28 (3): 179–86. doi:10.1046/j.1365-2710.2003.00477.x. PMID12795776.
Bühring KU, Sailer H, Faro HP, Leopold G, Pabst J, Garbe A (1986). “Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans”. J. Cardiovasc. Pharmacol.8 Suppl 11: S21–8. doi:10.1097/00005344-198511001-00004. PMID2439794.
Konishi, M.; Haraguchi, G.; Kimura, S.; Inagaki, H.; Kawabata, M.; Hachiya, H.; Hirao, K.; Isobe, M. (2010). “Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure”. Circulation journal : official journal of the Japanese Circulation Society74 (6): 1127–1134. doi:10.1253/circj.cj-09-0989. PMID20354334.
Leopold, G.; Pabst, J.; Ungethüm, W.; Bühring, K. U. (1986). “Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist”. Journal of clinical pharmacology26 (8): 616–621. doi:10.1002/j.1552-4604.1986.tb02959.x. PMID2878941.
“A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees”. Circulation90 (4): 1765–1773. (1994). doi:10.1161/01.cir.90.4.1765. PMID7923660.
Amabile, G.; Serradimigni, A. (1987). “Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: Comparative double-blind trial”. European heart journal8 Suppl M: 65–69. PMID2967187.
Thadani, U. (2004). “Current medical management of chronic stable angina”. Journal of cardiovascular pharmacology and therapeutics9 Suppl 1: S11–S29; quiz S29–9. PMID15378129.
Rosenberg, J.; Gustafsson, F. (2008). “Bisoprolol for congestive heart failure”. Expert Opinion on Pharmacotherapy9 (2): 293–300. doi:10.1517/14656566.9.2.293. PMID18201151.
Castagno, D.; Jhund, P. S.; McMurray, J. J. V.; Lewsey, J. D.; Erdmann, E.; Zannad, F.; Remme, W. J.; Lopez-Sendon, J. L. et al. (2010). “Improved survival with bisoprolol in patients with heart failure and renal impairment: An analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial”. European Journal of Heart Failure12 (6): 607–616. doi:10.1093/eurjhf/hfq038. PMID20354032.
Bristow, M. R.; Hershberger, R. E.; Port, J. D.; Minobe, W.; Rasmussen, R. (1989). “Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium”. Molecular pharmacology35 (3): 295–303. PMID2564629.
Haeusler G, Schliep HJ, Schelling P (1986). “High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol”. J. Cardiovasc. Pharmacol.8 Suppl 11: S2–15. doi:10.1097/00005344-198511001-00002. PMID2439793.
Harting J, Becker KH, Bergmann R (February 1986). “Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol”. Arzneimittelforschung36 (2): 200–8. PMID2870720.
Kaumann AJ, Lemoine H (October 1985). “Direct labelling of myocardial beta 1-adrenoceptors. Comparison of binding affinity of 3H-(−)-bisoprolol with its blocking potency”. Naunyn Schmiedebergs Arch. Pharmacol.331 (1): 27–39. doi:10.1007/bf00498849. PMID2866449.
Klockow M, Greiner HE, Haase A, Schmitges CJ, Seyfried C (February 1986). “Studies on the receptor profile of bisoprolol”. Arzneimittelforschung36 (2): 197–200. PMID2870719.
Manalan AS, Besch HR, Watanabe AM (August 1981). “Characterization of [3H](+/-)carazolol binding to beta-adrenergic receptors. Application to study of beta-adrenergic receptor subtypes in canine ventricular myocardium and lung”. Circ. Res.49 (2): 326–36. doi:10.1161/01.res.49.2.326. PMID6113900.
Schliep HJ, Schulze E, Harting J, Haeusler G (April 1986). “Antagonistic effects of bisoprolol on several beta-adrenoceptor-mediated actions in anaesthetized cats”. Eur. J. Pharmacol.123 (2): 253–61. doi:10.1016/0014-2999(86)90666-7. PMID3011461.
Schliep HJ, Harting J (1984). “Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs”. J. Cardiovasc. Pharmacol.6 (6): 1156–60. doi:10.1097/00005344-198406060-00024. PMID6084774.
Wellstein A, Palm D, Belz GG (1986). “Affinity and selectivity of beta-adrenoceptor antagonists in vitro”. J. Cardiovasc. Pharmacol.8 Suppl 11: S36–40. doi:10.1097/00005344-198511001-00006. PMID2439796.
Bundkirchen A, Brixius K, Bölck B, Nguyen Q, Schwinger RH (January 2003). “Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies”. Eur. J. Pharmacol.460 (1): 19–26. doi:10.1016/S0014-2999(02)02875-3. PMID12535855.
Nuttall SL, Routledge HC, Kendall MJ (June 2003). “A comparison of the beta1-selectivity of three beta1-selective beta-blockers”. J Clin Pharm Ther28 (3): 179–86. doi:10.1046/j.1365-2710.2003.00477.x. PMID12795776.
